1. Home
  2. KNSA vs CDLR Comparison

KNSA vs CDLR Comparison

Compare KNSA & CDLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • CDLR
  • Stock Information
  • Founded
  • KNSA 2015
  • CDLR 2008
  • Country
  • KNSA United Kingdom
  • CDLR Denmark
  • Employees
  • KNSA N/A
  • CDLR N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • CDLR
  • Sector
  • KNSA Health Care
  • CDLR
  • Exchange
  • KNSA Nasdaq
  • CDLR Nasdaq
  • Market Cap
  • KNSA 2.0B
  • CDLR 1.7B
  • IPO Year
  • KNSA 2018
  • CDLR N/A
  • Fundamental
  • Price
  • KNSA $26.03
  • CDLR $19.81
  • Analyst Decision
  • KNSA Strong Buy
  • CDLR Strong Buy
  • Analyst Count
  • KNSA 6
  • CDLR 1
  • Target Price
  • KNSA $38.00
  • CDLR $37.00
  • AVG Volume (30 Days)
  • KNSA 677.6K
  • CDLR 32.6K
  • Earning Date
  • KNSA 04-29-2025
  • CDLR 05-27-2025
  • Dividend Yield
  • KNSA N/A
  • CDLR N/A
  • EPS Growth
  • KNSA N/A
  • CDLR 229.37
  • EPS
  • KNSA N/A
  • CDLR 0.19
  • Revenue
  • KNSA $481,166,000.00
  • CDLR $257,519,412.00
  • Revenue This Year
  • KNSA $37.21
  • CDLR $106.55
  • Revenue Next Year
  • KNSA $1.53
  • CDLR $92.34
  • P/E Ratio
  • KNSA N/A
  • CDLR $24.83
  • Revenue Growth
  • KNSA 59.45
  • CDLR 128.99
  • 52 Week Low
  • KNSA $17.38
  • CDLR $17.37
  • 52 Week High
  • KNSA $28.56
  • CDLR $28.75
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 63.21
  • CDLR 46.24
  • Support Level
  • KNSA $25.97
  • CDLR $18.52
  • Resistance Level
  • KNSA $28.56
  • CDLR $22.61
  • Average True Range (ATR)
  • KNSA 1.24
  • CDLR 0.42
  • MACD
  • KNSA 0.36
  • CDLR -0.15
  • Stochastic Oscillator
  • KNSA 71.70
  • CDLR 31.54

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About CDLR Cadeler AS

Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning, and provides marine and engineering operations to the wind industry with a focus on safety and the environment. The company operates four offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.

Share on Social Networks: